DK2608789T4 - Terapeutiske anvendelser af 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazin - Google Patents

Terapeutiske anvendelser af 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazin Download PDF

Info

Publication number
DK2608789T4
DK2608789T4 DK11749331.2T DK11749331T DK2608789T4 DK 2608789 T4 DK2608789 T4 DK 2608789T4 DK 11749331 T DK11749331 T DK 11749331T DK 2608789 T4 DK2608789 T4 DK 2608789T4
Authority
DK
Denmark
Prior art keywords
phenylsulfanyl
piperazine
dimethyl
phenyl
therapeutic uses
Prior art date
Application number
DK11749331.2T
Other languages
Danish (da)
English (en)
Other versions
DK2608789T3 (en
Inventor
Marianne Dragheim
Ioana Florea
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2608789(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK2608789T3 publication Critical patent/DK2608789T3/en
Publication of DK2608789T4 publication Critical patent/DK2608789T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK11749331.2T 2010-08-23 2011-08-22 Terapeutiske anvendelser af 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazin DK2608789T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37588510P 2010-08-23 2010-08-23
DKPA201000739 2010-08-23
PCT/DK2011/050317 WO2012025123A1 (en) 2010-08-23 2011-08-22 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine

Publications (2)

Publication Number Publication Date
DK2608789T3 DK2608789T3 (en) 2017-05-15
DK2608789T4 true DK2608789T4 (da) 2024-11-04

Family

ID=44532506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11749331.2T DK2608789T4 (da) 2010-08-23 2011-08-22 Terapeutiske anvendelser af 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazin

Country Status (32)

Country Link
US (5) US20130184291A1 (https=)
EP (1) EP2608789B2 (https=)
JP (1) JP5902169B2 (https=)
KR (1) KR101816953B1 (https=)
CN (1) CN103068389A (https=)
AP (1) AP3583A (https=)
AR (1) AR082501A1 (https=)
AU (1) AU2011295465B8 (https=)
BR (2) BR122020025600A2 (https=)
CA (1) CA2807062C (https=)
CL (1) CL2013000492A1 (https=)
CO (1) CO6680652A2 (https=)
CY (1) CY1118886T1 (https=)
DK (1) DK2608789T4 (https=)
ES (1) ES2625142T5 (https=)
FI (1) FI2608789T4 (https=)
HR (1) HRP20170608T4 (https=)
HU (1) HUE034155T2 (https=)
IL (1) IL224371A (https=)
LT (1) LT2608789T (https=)
ME (1) ME02674B (https=)
MX (1) MX349724B (https=)
PL (1) PL2608789T5 (https=)
PT (1) PT2608789T (https=)
RS (1) RS55851B2 (https=)
RU (1) RU2564666C2 (https=)
SG (1) SG187649A1 (https=)
SI (1) SI2608789T2 (https=)
SM (1) SMT201700239T1 (https=)
TW (1) TW201212918A (https=)
WO (1) WO2012025123A1 (https=)
ZA (1) ZA201301385B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103418A (zh) 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DK0543584T3 (da) * 1991-11-18 1996-07-01 Lilly Industries Ltd Benzo(b)thiophen-2-carboxamider til behandling af forstyrrelser i centralnervesystemet
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
EP2090769A1 (en) 2000-10-02 2009-08-19 Rohr, Inc. Apparatus, method and system for gas turbine engine noise reduction
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
PL2044043T5 (pl) * 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity

Also Published As

Publication number Publication date
AR082501A1 (es) 2012-12-12
CO6680652A2 (es) 2013-05-31
HRP20170608T4 (hr) 2024-12-06
WO2012025123A1 (en) 2012-03-01
CA2807062C (en) 2018-07-31
SG187649A1 (en) 2013-03-28
IL224371A (en) 2016-07-31
ME02674B (me) 2017-06-20
US20240293397A1 (en) 2024-09-05
EP2608789A1 (en) 2013-07-03
AU2011295465B2 (en) 2014-06-19
LT2608789T (lt) 2017-05-25
AU2011295465B8 (en) 2014-07-10
EP2608789B2 (en) 2024-08-21
BR112013002194A2 (pt) 2016-05-31
ES2625142T5 (en) 2025-02-10
US20130184291A1 (en) 2013-07-18
HUE034155T2 (en) 2018-01-29
CN103068389A (zh) 2013-04-24
MX349724B (es) 2017-08-10
CA2807062A1 (en) 2012-03-01
PL2608789T5 (pl) 2025-11-12
RS55851B2 (sr) 2024-11-29
JP2013536206A (ja) 2013-09-19
RU2564666C2 (ru) 2015-10-10
SI2608789T2 (sl) 2025-05-30
SI2608789T1 (sl) 2017-06-30
PL2608789T3 (pl) 2017-09-29
AP3583A (en) 2016-02-09
TW201212918A (en) 2012-04-01
ES2625142T3 (es) 2017-07-18
BR122020025600A2 (pt) 2021-01-05
PT2608789T (pt) 2017-05-26
CY1118886T1 (el) 2018-01-10
JP5902169B2 (ja) 2016-04-13
EP2608789B1 (en) 2017-04-12
HRP20170608T1 (hr) 2017-07-28
AP2013006768A0 (en) 2012-03-31
US20190000836A1 (en) 2019-01-03
DK2608789T3 (en) 2017-05-15
KR101816953B1 (ko) 2018-01-09
US20210085674A1 (en) 2021-03-25
SMT201700239T1 (it) 2017-07-18
RU2013112890A (ru) 2014-09-27
MX2013001570A (es) 2013-03-21
US20220370439A1 (en) 2022-11-24
FI2608789T4 (fi) 2024-11-01
RS55851B1 (sr) 2017-08-31
CL2013000492A1 (es) 2013-06-07
AU2011295465A1 (en) 2013-02-07
KR20130097162A (ko) 2013-09-02
ZA201301385B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
DK2421534T3 (da) Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin
DK2398785T3 (da) Oprensning af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazin
CO7000771A2 (es) Proceso para la fabricación de 1-[2-(2,4-dimetilsulfanil)fenil]piperazina
LT3034497T (lt) 3,5-diamino-6-chlor-n-(n-(4-(4-(2-(heksil(2,3,4,5,6-penta-hidroksiheksil)amino)etoksi)fenil)butil)karbamimidoil)pirazin-2-karboksamidas
DK3686193T3 (da) 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
DK2470166T3 (da) Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin
EP2909775A4 (en) MANAGEMENT OF A MOBILE APPLICATION
CL2014003228A1 (es) Sintesis e intermediarios de compuestos heterocíclicos biologicamente activas.
ME03036B (me) 2-amin0-6-fluoro-n-( 5-fluoro-4-( 4-( 4-( oksetan -3-il)piperrazin -1-karbonil)piperidin-1-il)piridin-3-il )pirazol0[1,5alfa] pirimidin-3-karboksamid kao inhibitor atr kinaze
UY34202A (es) Compuestos fungicidas 2-(2-clor0-4-(4-cloro-fenoxi)-fenil]-1-(1,2,4]triazol-1-1l-etanol alquilo sustituidos
DK3415517T3 (da) Krystallinsk form af 1-(4-1-(2,6-difluorbenzyl)-5-dimethylaminomethyl-3-(6- methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin- 6yl)phenyl)-3-methoxyurea
PL2785181T3 (pl) Związki 2-(podstawiony fenylo)-cyklopentano-1,3-dionów i ich pochodne
HUE041725T2 (hu) (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya
DK2751973T3 (da) Fremgangsmåde til styring af tilgangen af en brugers personlige data
PL2658851T3 (pl) Związki heterocykliczne odpowiednie do leczenia dyslipidemii
IL225785A0 (en) Heterocyclic compounds, compositions comprising the same and uses thereof
BR112013010643A2 (pt) compostos heterocíclicos
DK2608789T4 (da) Terapeutiske anvendelser af 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazin
DK2925324T3 (da) Trans-4-{2-[4-(2,3-dichlorphenyl)-piperazin-1-yl]-ethyl}-n,ndimethylcarbamoyl- cyclohexylamin til behandling af negative symptomer på skizofreni
SMT201500069B (it) Composizioni farmaceutiche comprendenti n-(4-(2-ammino-3-cloropiridin-4-ilossi)-3-fluorofenil)-4-etossi-l-(4-fluorofenil)-2-osso-1,2-diidropiridin-3-carbossammide
TH148782B (th) รูปแบบปริมาณขนาดยาชนิดแข็งที่ให้ของ (S)-เอทธิล-2-อะมิโน-3-(4-(2-อะมิโน-6-((R)-1-(4-คลอโร-2-(3-เมทธิล-1H-ไพราซอล-1-อิล)ฟีนิล)-2,2,2-ไตรฟลูออโรเอทธอกซี) ไพริมิดิน-4-อิล)ฟีนิล)โพรพาโนเอต ((S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-y1)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate)